Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 04/12/23
Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent UpdatesPRNewsWire • 03/23/23
Regulus Therapeutics to Present at the SVB Securities Global Biopharma ConferencePRNewsWire • 02/09/23
Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical OperationsPRNewsWire • 11/29/22
Regulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent UpdatesPRNewsWire • 11/10/22
Regulus Therapeutics Announces Timing for Third Quarter 2022 Financial Results Webcast and Conference CallPRNewsWire • 11/03/22
Regulus Therapeutics Announces First Patient Dosed in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 11/02/22
Regulus Therapeutics Announces Positive Topline Safety and Pharmacokinetic (PK) Data from the Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 09/12/22
Regulus Therapeutics, Inc. (RGLS) CEO Joseph Hagan on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/11/22
Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent UpdatesPRNewsWire • 08/11/22
Regulus Therapeutics Announces Timing for Second Quarter 2022 Financial Results Webcast and Conference CallPRNewsWire • 08/04/22
Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 06/21/22
Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 06/13/22
Regulus Therapeutics to Present at the H.C. Wainwright Global Investment ConferencePRNewsWire • 05/17/22